# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Barclays analyst Etzer Darout initiates coverage on RAPT Therapeutics (NASDAQ:RAPT) with a Overweight rating and announces P...
Clear Street analyst Kaveri Pohlman maintains RAPT Therapeutics (NASDAQ:RAPT) with a Buy and raises the price target from $2...
RAPT Therapeutics, Inc. (NASDAQ: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, dev...
Leerink Partners analyst Thomas Smith upgrades RAPT Therapeutics (NASDAQ: RAPT) from Market Perform to Outperform and raises...
UBS analyst Eliana Merle maintains RAPT Therapeutics (NASDAQ:RAPT) with a Neutral and raises the price target from $8 to $9.
Wells Fargo analyst Yanan Zhu maintains RAPT Therapeutics (NASDAQ:RAPT) with a Overweight and lowers the price target from $...
RAPT Therapeutics (NASDAQ:RAPT) reported quarterly losses of $(0.65) per share which missed the analyst consensus estimate of $...
JP Morgan analyst Anupam Rama upgrades RAPT Therapeutics (NASDAQ:RAPT) from Underweight to Neutral and announces $14 price t...
LifeSci Capital initiates coverage on RAPT Therapeutics (NASDAQ:RAPT) with a Outperform rating and announces Price Target of ...